2021
DOI: 10.3390/curroncol28020124
|View full text |Cite
|
Sign up to set email alerts
|

The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review

Abstract: Background: The role of denosumab in patients with resectable giant cell tumour of bone remains unclear. We asked the following research question: for patients (aged ≥ 12 years) with resectable giant cell tumour of bone, what are the benefits and harms of denosumab compared with no denosumab in terms of (1) facilitation of surgery (operative time, blood loss), (2) disease recurrence, (3) pain control, (4) disease stability, and (5) adverse effects (e.g., malignant transformation, osteonecrosis of jaw, atypical… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
15
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
(15 citation statements)
references
References 21 publications
0
15
0
Order By: Relevance
“…Serial embolization and radiation therapy have been conducted in patients with such type of GCTB, but the treatment results are not favorable due to the high rate of recurrence and the risk of malignant transformation [3][4][5][6][7][8]. Denosumab, a monoclonal antibody inhibitor of RANKL, suppresses the osteoclast activity promoted by mononuclear tumor cells and induces new bone formation, thus improving bone stability [10][11][12]. Denosumab is currently a promising treatment for GCTB, especially for unresectable or advanced tumors [13][14][15][16].…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…Serial embolization and radiation therapy have been conducted in patients with such type of GCTB, but the treatment results are not favorable due to the high rate of recurrence and the risk of malignant transformation [3][4][5][6][7][8]. Denosumab, a monoclonal antibody inhibitor of RANKL, suppresses the osteoclast activity promoted by mononuclear tumor cells and induces new bone formation, thus improving bone stability [10][11][12]. Denosumab is currently a promising treatment for GCTB, especially for unresectable or advanced tumors [13][14][15][16].…”
Section: Discussionmentioning
confidence: 99%
“…However, the necessity of life-long injection may cause several problems, such as AEs, compliance to treatment, and economic problems. Severe AEs such as ONJ and malignant transformation have also been reported with long-term denosumab injection for GCTB [9][10][11]17]. It also involves several age-speci c problems related to school, job, and fertility in women, since GCTB is likely to occur in adolescents and young adults.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations